BeOne Medicines (ONC) Cash from Investing Activities (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Cash from Investing Activities data on file, last reported at -$45.5 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 62.68% year-over-year to -$45.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$199.7 million (up 56.63% YoY) and the FY2025 annual result came in at -$276.2 million, up 49.64% from the prior year.
• Cash from Investing Activities declined to -$45.5 million in Q1 2026 per ONC's latest filing, from -$38.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $658.7 million in Q2 2022 and bottomed at -$209.8 million in Q1 2024.
• The 5-year median for Cash from Investing Activities is -$49.3 million (2025), against an average of $15.7 million.
• The widest annual swing landed in 2022, when Cash from Investing Activities jumped 1512.96%; it then sank 263.76% in 2024.
• Tracing ONC's Cash from Investing Activities over 5 years: stood at $38.5 million in 2022, then tumbled by 262.4% to -$62.6 million in 2023, then plunged by 49.57% to -$93.6 million in 2024, then surged by 59.05% to -$38.3 million in 2025, then declined by 18.72% to -$45.5 million in 2026.
• Per Business Quant, the three latest ONC Cash from Investing Activities figures stand at -$45.5 million (Q1 2026), -$38.3 million (Q4 2025), and -$49.3 million (Q3 2025).

Peer Comparison